Navigation Links
Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
Date:10/29/2009

instruments, net of $2,005 as well as a gain on the extinguishment of a portion of the debt acquired from Indevus of $4,025.
  • To reflect the cash tax savings resulting from the Indevus acquisition and the tax effect of the pre-tax adjustments above at applicable tax rates.
  •     Nine months Ended         Actual
         September 30, 2008      Reported
         (unaudited)               (GAAP)  Adjustments        Adjusted
    
        Total Revenues           $913,200            $        $913,200
        Costs and expenses:
          Cost of revenues        190,554      (21,944)  (1)   168,610
          Selling, general and
           administrative         357,775      (12,481)  (2)   345,294
          Research and
           development             82,244      (10,491)  (3)    71,753
          Impairment of other
           intangibles              8,083       (8,083)  (4)
    
        Operating income          274,544       52,999         327,543
    
          Interest income, net     (8,292)      (6,620)  (5)   (14,912)
          Other income, net          (835)                        (835)
    
        Income before income
         taxes                    283,671       59,619         343,290
          Income taxes            101,021       22,631   (6)   123,652
    
        Net income               $182,650      $36,988        $219,638
    
        Diluted earnings per share  $1.45           --           $1.74
        Diluted weighted
         average shares           126,012           --         126,012
    
    
    
    

    Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:

    1. To exclude amortization of commercial intangible assets related to marketed products.
    2. To exclude separation costs of $10,459, impairment of long-lived assets of $1,482 and contract termination costs of $540.
    3. To exclude upfront and milestone payments to partners of $2,000, separation costs of $825, impairment of long lived assets of $3,115 and contract termination costs of $4,551.
    4. To exc
      '/>"/>

    SOURCE Endo Pharmaceuticals
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
    2. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
    3. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
    4. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    5. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
    6. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
    7. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
    8. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
    9. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
    10. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    11. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... , Sept. 2, 2015 Advanced Wound ... Summary Advanced dressings have steadily replaced traditional ... a variety of wound indications, such as trauma ... infection control, and physical protection become increasingly critical ... role in standard therapy. This report focuses ...
    (Date:9/2/2015)... , Sept. 2, 2015 Advanced ... Summary Advanced dressings have steadily replaced ... of a variety of wound indications, such as ... management, infection control, and physical protection become increasingly ... greater role in standard therapy. This report ...
    (Date:9/2/2015)... , Sept. 2, 2015 ... diversifies revenue base with highly profitable specialty products ... , Near-term growth potential with 11 product applications ... Paragraph IV certifications  , Provides medium and ... in development, including eight controlled substances , ...
    Breaking Medicine Technology:Advanced Wound Dressings - SA Analysis and Market Forecasts 2Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6
    ... WAYNE, Pa., Oct. 23 Escalon Medical Corp. (Nasdaq: ... Solutions subsidiary released its Web-Based AXIS(TM) Image Management System. ... images from different sources into a single searchable database ... over time across multiple imaging modalities, and improve practice ...
    ... , BOSTON, Oct. 23 Solos Endoscopy, Inc. (Pink ... has received additional purchase orders for its MammoView(TM) line ... (NCI), as well as the U.S. National Institute of ... of Health and Human Services. Solos Endoscopy,s MammoView(TM) line ...
    Cached Medicine Technology:Escalon(R) Subsidiary Escalon Digital Solutions Announces Release of Web-Based AXIS(TM) Image Management System 2Escalon(R) Subsidiary Escalon Digital Solutions Announces Release of Web-Based AXIS(TM) Image Management System 3Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line 2
    (Date:9/3/2015)... ... ... is an unavoidable result of incision or injury to the skin. Unsightly as it may ... appearance of a scar is dependent on many factors – the size and depth of ... to near invisibility on their own over a period of months,” says Dr. Jocelyn ...
    (Date:9/3/2015)... ... , ... “Love in Tokyo” an independent romantic comedy film by Michael Solton ... and will be released on DVD early next year, by Maverick Entertainment. The film ... and singer/songwriter, and Jason London, lead from “Dazed and Confused.” , “Love in ...
    (Date:9/3/2015)... ... 2015 , ... Representatives with State Farm Agent EJ Roberts ... Gulf Babypalooza on September 19, 2015. , “We will be providing information to ... We will be discussing setting up college funds, offering information specific to their ...
    (Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we have seen ... traditional health care model, where the primary care physician dictates and the patient obeys. ... become educated about their health issues and empowered to choose their own treatment options. ...
    (Date:9/3/2015)... ... 03, 2015 , ... About 220,800 new cases of prostate cancer are reported each year, along ... with prostate cancer during their lifetime. While only one man in 10,000 will typically get ... age 65, according to the American Cancer Society. , Prostate cancer ...
    Breaking Medicine News(10 mins):Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
    ... Care Physician Recruitment, ORLANDO, Fla., Nov. 10 ... - with primary care,being especially hard hit. As the ... shortage promises to get worse with major,repercussions for the ... working to address this issue with a new policy ...
    ... - BELLUS Health Inc. (NASDAQ:,BLUS; TSX: BLU) reports ... For the three-month period ended September 30, 2008, ... compared to $13,889,000 ($0.29,per share) for the corresponding ... September 30, 2008, the net loss amounted to,$36,703,000 ...
    ... Adds Fuel to Double-Digit Growth in Europe, PROVO, ... (NYSE: NUS ) opened for business in the ... adds further fuel to the,company,s increasingly successful European region., ... the,Czech Republic is becoming a dynamic market for direct ...
    ... 10 Medipacs, Inc., a Tucson based,drug delivery ... and Agustin Vilches, RPh to the company,s medical ... and together have practiced,in Hospital, Hospice and Home ... years at Swedish Hospital Medical,Center and the Fred ...
    ... and Address Vital Breast Cancer Health ... Care Issues for All Illinois Residents, SPRINGFIELD, Ill., Nov. 10 ... of the global breast cancer movement,will convene at the first-ever Komen ... state,s breast health coverage, discuss,the impact of statewide breast health programs ...
    ... Nov. 10 Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... results on November 13, 2008, before the open,of U.S. ... and live audio webcast to discuss the results and ... Time/5:30 a.m. Pacific,Time., The live webcast and press ...
    Cached Medicine News:Health News:AMA Works to Reverse Primary Care Physician Shortage 2Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 2Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 3Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 4Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 5Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 6Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 7Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 8Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 9Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 10Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 11Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 12Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 13Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 14Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 15Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 16Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 17Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 18Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 19Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 20Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 21Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 22Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 23Health News:Nu Skin Enterprises Opens the Czech Republic 2Health News:Medipacs Appoints Advisory Board Members 2Health News:Susan G. Komen for the Cure(R) Hosts Inaugural Illinois State Summit in Springfield 2Health News:Jazz Pharmaceuticals, Inc. to Announce Third Quarter Financial Results on November 13, 2008 2
    Indicated for procedures of the wrist, ankle, elbow, and other small joints, the,UltrAblator is effective for ablation of soft tissue and coagulation of bleeders,encountered during surgery....
    ... is designed to replace the carpal scaphoid bone. ... pole which fits under a shelf formed in ... suture hole on the proximal hole for suture ... the early postoperative period until a firm capsuloligamentous ...
    ... has the same anatomical configuration as the ... to provide for stability. The implant has ... use in suture fixation through the scaphoid ... while a capsuloligamentous system forms around the ...
    ... The Diamond plate is designed for ... lunate and triquetrum bones in the hand. ... patients suffering from pain and/or loss of ... post-traumatic arthritis, fractures, carpal instability or rheumatoid ...
    Medicine Products: